 European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP recommended granting marketing authorization to Albireo Pharma Incs NASDAQ: ALBO Bylvay odevixibat for the treatment of Progressive Familial Intrahepatic Cholestasis PFIC in patients aged six months or older. PFIC is a rare, life-threatening liver disease, and only about half of the children affected by the disease survive beyond the age of 10 years. 